VYXEOS Drug Patent Profile

Which patents cover Vyxeos, and when can generic versions of Vyxeos launch?

Vyxeos is a drug marketed by Jazz Pharms Therap and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-six countries.

The generic ingredient in VYXEOS is cytarabine; daunorubicin. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cytarabine; daunorubicin profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyxeos

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 30, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VYXEOS

International Patents:	147
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYXEOS

US Patents and Regulatory Information for VYXEOS

VYXEOS is protected by eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,518,437		Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	10,835,492*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,022,279*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	10,166,184*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	10,028,912*PED				Y

International Patents for VYXEOS

See the table below for patents covering VYXEOS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2011157376	LIPOSOME LOADING WITH METAL ION
World Intellectual Property Organization (WIPO)	2013059133
China	101657098	Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
Spain	2750368
Canada	2678332	RAPPORTS PHARMACOLOGIQUES FIXES DANS LE TRAITEMENT DES CANCERS HEMATOPOIETIQUES ET DES AFFECTIONS PROLIFERATIVES (FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS ANDPROLIFERATIVE DISORDERS)

Supplementary Protection Certificates for VYXEOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2768484	C201930069	Spain		PRODUCT NAME: COMBINACION DE DAUNORUBICINA Y CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823
2768484	384 1-2020	Slovakia		PRODUCT NAME: KOMBINACIA DAUNORUBICINU A CYTARABINU; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484	CR 2019 00051	Denmark		PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827
3300601	22C1034	France		PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484	132019000000144	Italy		PRODUCT NAME: DAUNORUBICINA E CITARABINA(VYXEOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1308, 20180827

VYXEOS Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What is VYXEOS?

VYXEOS (cytarabine and daunorubicin liposome injection) is a combination chemotherapy developed by Jazz Pharmaceuticals. It targets acute myeloid leukemia (AML), specifically newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. Approved by the FDA in December 2017, VYXEOS is marketed under the brand name Vyxeos Liposomal in the U.S.

Market Position and Sales Dynamics

Market Size and Growth

The AML drug market is estimated at $400 million annually in the U.S. (IQVIA, 2022). AML treatment primarily involves chemotherapy, with limited targeted therapies. VYXEOS captured approximately 20% of new AML cases in 2022, translating to roughly $80 million in U.S. sales.

Competitive Landscape

• Standard of Care (SOC): Cytarabine with daunorubicin administered separately.
• Major competitors: Azacitidine, decitabine, and emerging targeted therapies such as venetoclax-based regimens.
• VYXEOS advantage: Delivers both agents in a fixed-dose liposomal formulation, improving pharmacokinetics and potentially efficacy.

Sales Trajectory

• 2018: $20 million
• 2019: $50 million
• 2020: $80 million
• 2021: $115 million
• 2022: $180 million

Growth propelled by increased adoption, expanded labeling, and clinical evidence supporting superior outcomes.

R&D and Market Expansion Potential

Clinical Trials and Pipeline

• Ongoing trials: VYXEOS is being tested for other hematologic malignancies, including high-risk myelodysplastic syndromes (MDS).
• Combination studies: With targeted agents like FLT3 inhibitors and BCL-2 inhibitors.
• Results could broaden indications and market size.

Global Approvals and Penetration

• Europe: Approved in 2018; sales are emerging, with initial uptake.
• Asia-Pacific: Pending approval; market size estimated at $100 million cumulatively.
• Strategies include licensing agreements and direct marketing.

Financial Fundamentals

Revenue and Profitability

Year	Revenue (USD millions)	Net Income (USD millions)	Operating Margin
2020	80	10	10%
2021	115	25	22%
2022	180	50	28%

Cost Structure

• R&D: Approximately 12% of revenue, aligned with ongoing clinical trials.
• Manufacturing: High due to liposomal formulation complexity.
• Marketing: Focused on specialist physicians; marketing expense increased with sales growth.

Margins and Cash Flow

• Gross margin: 65%
• EBITDA margin: 30%
• Free cash flow: Positive, supporting ongoing R&D and pipeline investments.

Regulatory and Policy Environment

• FDA approval in 2017 under accelerated approval, requiring confirmatory trials.
• Price: List price around $40,000 per treatment course.
• Reimbursement: Favorable, with coverage by Medicare, Medicaid, and private insurers.

Pricing and Reimbursement Dynamics

• Price competitiveness depends on demonstrated improved outcomes.
• Payer negotiations: Critical for market expansion, especially outside the U.S.

Investment Factors and Risks

Key Strengths

• Proven efficacy in AML with a niche market share.
• Strong clinical data supporting survival benefits.
• Increasing adoption in U.S. hospitals.

Challenges

• Competition from emerging targeted therapies.
• High manufacturing costs of liposomal formulations.
• Regulatory risks related to expansion trials.

Financial Risks

• Revenue growth dependent on continued market penetration.
• Pricing pressure from payers could impact margins.
• Dependence on a limited pipeline of indications.

Competitive Outlook and Strategic Options

• Potential for pipeline expansion into MDS and other hematologic malignancies.
• Strategic licensing or partnership agreements to accelerate international growth.
• Cost optimization in manufacturing to support margin preservation.

Key Takeaways

VYXEOS exhibits consistent revenue growth driven by clinical efficacy and market adoption within a niche AML indication. Its current valuation reflects an optimistic outlook balancing market expansion potential against competitive and regulatory risks. Continued pipeline development and international market penetration are critical for sustained valuation growth.

FAQs

What is the primary indication for VYXEOS?

Treatment of newly diagnosed therapy-related AML or AML with myelodysplasia-related changes in adults.

How does VYXEOS differ from standard chemotherapy?

It combines cytarabine and daunorubicin in a liposomal formulation, improving pharmacokinetics and potentially enhancing efficacy.

What are the main growth drivers for VYXEOS?

Increased physician adoption, expanded indications, and pipeline developments in other hematologic conditions.

What are the regulatory hurdles ahead?

Confirmatory trials required by the FDA, plus potential approvals in Europe and Asia for broader market access.

How does pricing impact VYXEOS's market penetration?

Pricing at around $40,000 per course is justified by clinical benefits but faces pressure from payers, influencing access and sales growth.

---

References

1. IQVIA. (2022). Pharmaceutical Market Data.
2. Jazz Pharmaceuticals. (2023). VYXEOS Product information and clinical data.
3. FDA. (2017). Approval of Vyxeos Liposomal.
4. European Medicines Agency. (2018). VYXEOS marketing authorization.
5. MarketWatch. (2022). AML therapeutics market analysis.